ADTX ADiTx Therapeutics Inc.

2.94
-0.02  -1%
Previous Close 2.96
Open 2.99
52 Week Low 1.62
52 Week High 9.58
Market Cap $42,601,332
Shares 14,490,249
Float 12,423,023
Enterprise Value $34,227,184
Volume 279,977
Av. Daily Volume 1,166,186
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
ADi
Psoriasis
Phase 1/2
Phase 1/2
Phase 1/2 trial planned.

Latest News

  1. MOUNTAIN VIEW, Calif., April 6, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that HealthBar will be offering AditxtScore™ for COVID-19 throughout the State of Michigan.

    HealthBar provides on-demand healthcare services to consumers and businesses across its service areas. The company offers drive-thru and concierge COVID-19 testing, including rapid, PCR, antibody, and antigen tests. HealthBar also partners with organizations to provide at-location testing for employees as well as an expanding menu of medical services.

    As an AditxtScore™ Channel Partner, HealthBar will now offer its consumer and employer clients AditxtScore™ for COVID-19 as an immune monitoring service. This service will complement HealthBar's current offerings and provide key information regarding immunity status. Aditxt's CLIA-certified AditxtScore™ Center will process specimens collected by HealthBar.

    Nathan Baar, Founder and CEO of HealthBar, said, "It's crucial that we provide the best testing options available as businesses and schools begin to open across the State of Michigan. Aditxt's unique immune monitoring technology backed by leading experts within the field provides unmatched information on protective immunity against COVID-19 and is a great addition to our roster of tests."

    Amro Albanna, co-founder and CEO of Aditxt, added, "As we learn more about COVID-19,  monitoring the immune system will be key to understanding a person's level of immunity. We're excited to begin working with the HealthBar team and expanding our AditxtScore™ Channel Partner network."

    For more information on AditxtScore™ and how it can bolster your COVID-19 testing efforts, visit aditxtscore.com.

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    About HealthBar

    HealthBar is a custom healthcare services company providing on-demand, concierge medical care to a wide variety of clients and industries. Their goal is to change how healthcare is delivered to provide a more consumer friendly, transparent model of service. Their services can be ordered as a package or independently. Improving access, reducing cost and focusing on healthy lifestyles and habits drive their core mission of reducing an individual's dependence on the healthcare system. You can learn more at www.healthbar.com.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section titled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. 

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/healthbar-becomes-aditxtscore-channel-partner-to-offer-aditxtscore-for-covid-19-immunity-status-monitoring-to-complement-its-concierge-and-drive-thru-testing-services-301262830.html

    SOURCE Aditx Therapeutics, Inc.

    View Full Article Hide Full Article
  2. MOUNTAIN VIEW, Calif., April 1, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centers.  Collection Sites, LLC is owned and operated by Medivolve Inc. ("Medivolve") ((NEO:MEDV, OTC:COPRF, FRA:4NC)).

    Collection Sites, LLC provides testing programs to various organizations and customers in different industries, including entertainment, travel, and education. As an AditxtScore™ Channel Partner, Collection Sites, LLC will now offer its customers AditxtScore™ for COVID-19 as an immune monitoring service. Collection Sites, LLC can implement the test with current staff and no additional investment. Specimens collected by Collection Sites will be sent to, and processed at, Aditxt's CLIA-certified AditxtScore™ Center.

    "We welcome Collection Sites, LLC as an AditxtScore™ Channel Partner and we look forward to working with their team to expand the availability of AditxtScore™ for COVID-19 through their mobile testing centers," said Amro Albanna, co-Founder and CEO of Aditxt.

    "As the rollout of COVID-19 vaccines progress across the United States, people are going to want to monitor their immunity levels regularly," added Medivolve CEO, Doug Sommerville. "This will be one of the many ongoing services offered through our future telehealth sites as immune responsiveness will be top of mind for people for the foreseeable future. We are excited to be able to bring this testing modality to our customers and believe it will be a significant revenue contributor over the coming now and in the future."

    For more information on AditxtScore™ and how it can bolster your COVID-19 testing efforts, visit www.aditxtscore.com  

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    About Medivolve Inc.

    Medivolve Inc. ((NEO:MEDV, OTC:COPRF, FRA:4NC))  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment. Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space.  Medivolve's primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. For more information, please visit www.medivolve.ca.

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

     

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/collection-sites-llc-named-aditxtscore-channel-partner-to-offer-aditxtscore-for-covid-19-immunity-status-monitoring-through-its-mobile-testing-centers-301260470.html

    SOURCE Aditx Therapeutics, Inc.

    View Full Article Hide Full Article
  3. TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Medivolve Inc. ("Medivolve") ((NEO:MEDV, OTC:COPRF, FRA:4NC)) today announced that its wholly owned subsidiary, Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centres. Aditx Therapeutics (NASDAQ:ADTX), is a biotech innovation company focused on improving the health of the immune system.

    Collection Sites, LLC provides testing programs to various organizations and customers in different industries, including entertainment and education. As an AditxtScore™ Channel Partner, Collection Sites, LLC will now offer its customers AditxtScore™ for COVID-19 as an immune monitoring service. Collection Sites, LLC can implement the test with current staff and no additional…

    TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Medivolve Inc. ("Medivolve") ((NEO:MEDV, OTC:COPRF, FRA:4NC)) today announced that its wholly owned subsidiary, Collection Sites, LLC will offer AditxtScore™ for COVID-19 through its mobile testing centres. Aditx Therapeutics (NASDAQ:ADTX), is a biotech innovation company focused on improving the health of the immune system.

    Collection Sites, LLC provides testing programs to various organizations and customers in different industries, including entertainment and education. As an AditxtScore™ Channel Partner, Collection Sites, LLC will now offer its customers AditxtScore™ for COVID-19 as an immune monitoring service. Collection Sites, LLC can implement the test with current staff and no additional investment. Specimens collected by Collection Sites will be sent to and processed at Aditxt's CLIA-certified AditxtScore™ Centre.

    "We welcome Collection Sites as an AditxtScore Channel Partner and we look forward to working with their team to expand the availability of AditxtScore for COVID-19 through their mobile testing centres," said Amro Albanna, co-Founder and CEO of Aditxt.

    "As the rollout of COVID-19 vaccines progress across the United States, people are going to want to monitor their immunity levels regularly," added Medivolve CEO, Doug Sommerville. "This will be one of the many ongoing services offered through our future telehealth sites as immune responsiveness will be top of mind for people for the foreseeable future. We are excited to be able to bring this testing modality to our customers and believe it will be a significant revenue contributor now and in the future."

    Corporate Update

    Medivolve is also pleased to provide a corporate update on certain of its historical investments. Medivolve has amended its agreement with Sunnybrook Research Institute ("Sunnybrook") and Amino Therapeutics, Inc. ("Amino") and also terminated its agreement with Sinai Health System ("Mount Sinai"). All three agreements were initially entered into in early 2020 when the company was still an investment issuer. These updates reduce future capital investment in their respective research programs, allowing the company to focus solely on its current telehealth strategy. Further, Medivolve has divested its interest in Athletics & Health Solutions and Eco Capital Growth Corp. for nominal consideration as these entities no longer fit with the company's business strategy.

    "While we believe researchers at Mount Sinai, Sunnybrook and Amino are performing valuable work, at this time management has determined it is more advantageous for the Company to focus on its telehealth strategy," commented Doug Sommerville, Medivolve CEO. "By reducing the future capital investments required by these agreements, we can more efficiently deploy our capital to grow Medivolve's telehealth and diagnostics business."

    Specifically, Medivolve has terminated the Mount Sinai agreement, relinquishing its rights to the Royalty and Option on any commercial IP developed as part of the agreement. This termination eliminates $375,000 of aggregate research investment that would be owed to Mount Sinai. Further, Medivolve has amended its Sunnybrook agreement to reduce its royalty interest in half in exchange for a 50% reduction in the consideration payable to Sunnybrook. Medivolve also amended its share purchase agreement with Amino to reduce the company's equity ownership interest in Amino to 10% in exchange for a release of all outstanding payments still owing to Amino.

    About Medivolve Inc.

    Medivolve Inc. ((NEO:MEDV, OTC:COPRF, FRA:4NC))  seeks out disruptive technologies, ground-breaking innovations, and exclusive partnerships to help combat COVID-19 and generate remarkable risk-adjusted returns for investors. Specifically, Medivolve offers investors a diversified investment in the COVID-19 medical space across three areas; prevention, detection, and treatment.

    Medivolve has a team of renowned global medical and business advisors that have developed a proprietary business strategy to capitalize on high-margin opportunities in the COVID-19 space. This panel includes prominent immunologist Dr. Lawrence Steinman and Dr. Glenn Copeland, who has 45 years of experience in orthopaedic treatment, foot and ankle care, and sports medicine.

    Medivolve's primary focus is to provide convenient and assessable medical services for testing of the COVID-19 virus to help combat the pandemic. This is achieved largely through two acquisitions: 100% of Collection Sites, LLC and 28% of Colombian Sanaty IPS. Collection Sites is setting up a series of COVID-19 testing sites across the United States with appointments and payments will be handled through the online portal  www.testbeforeyougo.com. Sanaty is setting up a series of full-service medical clinics offering a complete COVID-19 testing solution.

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The immune reprogramming technology is currently at the pre-clinical stage and is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    For additional information, please contact:

    Doug Sommerville, CEO

     

    For investing inquiries please contact:

    For US media enquires please contact:

    Veronica Welch

    Aditx Therapeutics Media Contact

    Public Relations

    Kevin Harrington

    5W Public Relations

    Cautionary Note Regarding Forward-looking Information

    This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Forward-looking information includes, but is not limited to, statements with respect to the distribution agreement with Aditxt Therapeutics Inc.; the proposed roll-out of Aditxt tests; the Company's expectations for the demand for such tests; projected timelines for testing results; projected revenues from the testing; the pursuit by Medivolve of opportunities; and the merits or potential returns of any such opportunities. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

    NEITHER THE NEO STOCK EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAS REVIEWED OR ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE. 



    Primary Logo

    View Full Article Hide Full Article
  4. MOUNTAIN VIEW, Calif., March 24, 2021 /PRNewswire/ -- Aditx Therapeutics, Inc. (Aditxt) (the "Company") (NASDAQ:ADTX), a biotech innovation company focused on improving the health of the immune system, today announced that its AditxtReprogrammingTM Therapeutics Division is preparing its therapeutic program for psoriasis for First-In-Human clinical trials. The trials, which are planned to begin in Q4 2021, will evaluate clinical safety and efficacy of Aditxt's new approach to reprogramming and retraining the immune system.

    The Trials will be evaluating a nucleic acid-based technology named Apoptotic DNA Immunotherapy™ (ADi™). Aditxt's ADi™ technology utilizes a novel approach that mimics the way the body naturally induces tolerance to its own tissues (therapeutically induced immune tolerance) and is protected with approximately 90 U.S. and international patents. ADi™ has demonstrated efficacy in several pre-clinical disease models including psoriasis in which a reduction in skin thickening and scaling, and modulation of key protein markers were observed.

    Aditxt has signed an agreement with a regulatory consultant based in Munich, Germany, which will play a central role in navigating the first AditxtReprogrammingTM therapeutic program through the clinical trial and regulatory process.  The firm will work with the Aditxt's AditxtReprogrammingTM team to submit an Investigational New Drug application (IND) to the regulatory agency in Germany.  Psoriasis is the first indication being targeted for clinical trial in the AditxtReprogrammingTM therapeutics pipeline. Other candidates that are advancing toward clinical trials include ADi™ for type 1 diabetes and skin allografting.

    Amro Albanna, co-founder and Chief Executive Officer of Aditxt, stated, "this agreement represents a major step forward as we begin advancing ADi™ for psoriasis through the regulatory process and towards the start of clinical trials. Our co-founder and Chief Innovation Officer, Dr. Shahrokh Shabahang, and his product development team have experience working within the regulatory framework of both the U.S. and Europe and are leading all preparation, execution, regulatory and budgetary matters relating to Aditxt's planned 2021 Phase I/IIA clinical trials for psoriasis. We are excited to begin this phase of Aditxt's development after our initial focus on launching the AditxtScoreTM  platform for monitoring the immune system."

    For more information about AditxtReprogrammingTM, visit aditxt.com/.

    About Aditx Therapeutics

    Aditxt is developing technologies specifically focused on improving the health of the immune system through immune monitoring and reprogramming. The Company's immune monitoring technology is designed to provide a personalized comprehensive profile of the immune system. The Company's immune reprogramming technology is designed to retrain the immune system to induce tolerance with an objective of addressing rejection of transplanted organs, autoimmune diseases, and allergies. For more information, please visit: www.aditxt.com

    Forward-Looking Statements

    Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws. Forward looking statements include statements regarding the Company's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things, the Company's ongoing and planned product development; the Company's intellectual property position; the Company's ability to develop commercial functions; expectations regarding product launch and revenue; the Company's results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and strategies; the industry in which the Company operates; and the trends that may affect the industry or the Company. Forward-looking statements are not guarantees of future performance and actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, as well as those risks more fully discussed in the section entitled "Risk Factors" in the Company's prospectus, dated February 10, 2021, that was filed with the Securities and Exchange Commission under File No. 333-252711, as well as discussions of potential risks, uncertainties, and other important factors in the Company's subsequent filings with the Securities and Exchange Commission. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/aditxt-to-initiate-first-in-human-clinical-trials-with-its-therapeutics-programs-in-psoriasis-by-year-end-301254455.html

    SOURCE Aditxt

    View Full Article Hide Full Article
  5. Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Aditxt (NASDAQ:ADTX) will be presenting at the Benzinga Biotech Small Cap Conference taking place on March 24-25, 2021. We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.

    Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/biotech/

    About the Benzinga Biotech Small Cap Conference

    The Benzinga Biotech Small Cap Conference bridges the gap between biotech companies, investors, and traders. Discover the companies in the biotech space who are helping to bring the world back to normalcy in the wake of the COVID-19 pandemic.

    For…

    Detroit, Michigan--(Newsfile Corp. - March 22, 2021) - Aditxt (NASDAQ:ADTX) will be presenting at the Benzinga Biotech Small Cap Conference taking place on March 24-25, 2021. We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.

    Sign up to get a free spectator pass for the event: https://www.benzinga.com/events/small-cap/biotech/

    About the Benzinga Biotech Small Cap Conference

    The Benzinga Biotech Small Cap Conference bridges the gap between biotech companies, investors, and traders. Discover the companies in the biotech space who are helping to bring the world back to normalcy in the wake of the COVID-19 pandemic.

    For more information and/or to register for the conference please visit: https://www.benzinga.com/events/small-cap/biotech/

    We look forward to seeing you there.

    For further information:

    Aditxt
    Jeff Ramson
    646-863-6341

    www.aditxt.com

    View Full Article Hide Full Article
View All ADiTx Therapeutics Inc. News